Friday, August 24, 2018 8:41:47 AM
Alert
Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Intraday Stock Chart
Today : Friday 24 August 2018
Click Here for more Adverum Biotechnologies, Inc. Charts.
- ADVM-053 is a novel gene therapy candidate designed as a potential single-administration treatment for hereditary angioedema (“HAE”)
- Plans to submit an Investigational New Drug (IND) application to the FDA for ADVM-053 in 4Q18
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ADVM-053, a preclinical gene therapy candidate being investigated as a potential single-administration treatment which has the potential to provide sustained levels of the C1 esterase inhibitor (“C1EI”) protein.
HAE affects approximately 8,000 individuals in the U.S. This disease is caused by a genetic mutation that results in low levels of C1 esterase inhibitor which can be associated with sudden swelling and edema of respiratory airways, gastrointestinal tract, and extremities.
“We are pleased to receive the Orphan Drug Designation for ADVM-053 from the FDA," said Leone Patterson, interim president and chief executive officer of Adverum Biotechnologies. “We are committed to developing effective treatments for patients living with HAE and the support from the FDA will be invaluable towards this goal. We look forward to submitting our IND application in the fourth quarter.”
Orphan drug designation is granted by the FDA to novel drugs and biologics, which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S. The designation provides incentives for sponsors to develop products for rare diseases, which may include tax credits towards the cost of clinical trials and prescription drug user fee waivers. The orphan drug designation also could entitle Adverum Biotechnologies to a seven-year period of marketing exclusivity in the United States for ADVM-053 should the company receive FDA approval for the treatment of HAE for this product candidate.
Recent ADVM News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:38:02 PM
- Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting • GlobeNewswire Inc. • 07/17/2024 06:45:00 AM
- Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:07:03 PM
- Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/11/2024 08:19:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:16:53 PM
- Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors • GlobeNewswire Inc. • 06/11/2024 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/28/2024 06:00:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:13:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:10:27 PM
- Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Adverum Biotechnologies to Participate in Upcoming May Investor Conferences • GlobeNewswire Inc. • 05/03/2024 12:00:00 PM
- Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates • GlobeNewswire Inc. • 03/18/2024 08:05:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/04/2024 09:40:18 PM
- Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/22/2024 08:47:57 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/21/2024 08:39:59 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 09:17:58 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:26:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:33:10 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 09:27:22 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:05:38 PM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM